Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. Investors

Core Viewpoint - The Portnoy Law Firm is advising investors of Aquestive Therapeutics, Inc. to join a class action lawsuit due to alleged misleading statements regarding the approval of their New Drug Application for Anaphylm, which led to significant stock price decline [1][3][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026 [1]. - Investors have until May 4, 2026, to file a lead plaintiff motion [1]. - The lawsuit claims that Aquestive misrepresented its progress towards FDA approval for Anaphylm, leading to a false impression of readiness for approval by the January 31, 2026, PDUFA date [3]. Group 2: Allegations and Impact - The lawsuit alleges that the FDA identified deficiencies in the NDA for Anaphylm, which prevented discussions on labeling and post-marketing commitments [3]. - Following the disclosure of these deficiencies on January 9, 2026, Aquestive's stock price fell by more than 37% [4]. - The firm emphasizes that for the FDA to grant approval, all identified deficiencies must be remedied, indicating a delay in the launch of Anaphylm [3].